A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This trial is an open and multicenter phase Ib/II clinical study, which aims to evaluate the
safety, tolerability, PK characteristics, immunogenicity, and effectiveness.